Anokion Elects Michael Clayman, M.D., as Chairman of its Board of Directors

LAUSANNE, Switzerland, & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Anokion (“Anokion” or the “Company”), a privately held biopharmaceutical
company developing novel tolerance-inducing therapeutics for autoimmune
diseases, today announced that Michael D. Clayman, M.D., president,
chief executive officer, and director of Flexion Therapeutics, has been
elected as non-executive chairman of Anokion’s board of directors (“the
Board”). Dr. Clayman has been an independent director of Anokion since
February 2016. In his new role as chairman he is replacing Jeffrey
Hubbell, Ph.D., who will remain on the Board as a director.

“We are grateful to Jeff for his significant contributions chairing
Anokion’s Board. During his tenure, the Company opened a site in
Cambridge, MA, and expanded its novel tolerance-inducing portfolio for
autoimmune diseases,” said John Hohneker, M.D., president and chief
executive officer of Anokion. “We are also excited to welcome Mike to
his new role. His expertise in company building and biopharmaceutical
product development across a range of therapeutic indications will no
doubt prove invaluable to us as we continue to progress our lead program
in multiple sclerosis toward the clinic.”

“In working alongside the Anokion team, I have been impressed by their
passion, scientific rigor, and commitment to bringing new medicines to
patients in need,” said Dr. Clayman. “Anokion is translating immune
tolerance mechanisms into novel therapies, and I look forward to
collaborating with the leadership team and my fellow board members to
help the Company advance its pipeline.”

Dr. Clayman co-founded Flexion Therapeutics and also serves on the board
of directors of Akebia Therapeutics. Previously, Dr. Clayman served in
senior management positions at Eli Lilly and Company (Lilly), most
recently as vice president, Lilly Research Laboratories, general manager
of Chorus, Lilly’s early phase development accelerator and Chair of the
Lilly Bioethics Committee. Prior to Lilly, Dr. Clayman was an Assistant
Professor in the School of Medicine at the University of Pennsylvania,
where his research centered on the immunopathogenesis of renal disease.
Additionally, Dr. Clayman is the recipient of the Physician Scientist
Award from the National Institutes of Health. Dr. Clayman earned a B.A.,
cum laude, from Yale University and an M.D. from the University of
California San Diego School of Medicine. Following an internship and
residency in Internal Medicine at the University of California, San
Francisco Moffitt Hospitals, Dr. Clayman completed clinical and research
fellowships in nephrology at the University of Pennsylvania.

About Anokion

Anokion, a spin-off from the Ecole Polytechnique Fédérale de Lausanne
(EPFL), is focused on applying the company’s antigen-specific immune
tolerance technology to treat autoimmune and allergic diseases and
reduce the immunogenicity of therapeutic proteins. As a platform
technology, Anokion’s approach to antigen-specific immune tolerance can
be translated to virtually any protein in numerous clinical indications.
Anokion’s investors include Versant Ventures, Novo Ventures, Novartis
Venture Fund and a group of individual investors. For more information,
please visit www.anokion.com.

Contacts

Anokion
Deb Geraghty, Ph.D., +1-857-320-6635
deb.geraghty@anokion.com